ARHGEF1

ARHGEF1 (p115 RhoGEF) is a Gα12/13-regulated guanine nucleotide exchange factor for RhoA that couples heterotrimeric G protein signaling to cytoskeletal remodeling, cell adhesion, vascular tone, immune cell trafficking, and apoptotic cell extrusion. Its N-terminal RGS domain functions as a GTPase-activating protein selective for Gα12 and Gα13 (PMID:9641915), while activated Gα13 binds the DH domain at a site distinct from the RhoA-binding surface to relieve autoinhibition imposed by an interdomain linker, as revealed by crystallography and SAXS (PMID:21064165, PMID:22661716); Gα13-driven palmitoylation-dependent translocation to the plasma membrane further potentiates signaling (PMID:10747909, PMID:18320579). Tyrosine phosphorylation by JAK2 (Tyr738, downstream of angiotensin II) or Src-family kinases activates ARHGEF1-dependent RhoA and Rac1 signaling in vascular smooth muscle, leukocytes, and platelets, and smooth-muscle-specific knockout confers resistance to angiotensin II-induced hypertension (PMID:20098430, PMID:27986909, PMID:29130930). Loss-of-function mutations in human ARHGEF1 cause impaired RhoA-mediated actin polymerization and dysregulated AKT signaling in lymphocytes, resulting in primary immunodeficiency (PMID:30521495).

1. 1998 High

   Establishing that p115 RhoGEF is both a GAP for Gα12/13 and the effector through which Gα13 directly stimulates RhoA exchange activity resolved the long-standing question of how G12/13-coupled receptors activate Rho GTPases.

   Evidence In vitro reconstitution with recombinant proteins measuring GTPase acceleration and nucleotide exchange

   PMID:9641915 PMID:9641916

   Open questions at the time

   • Structural basis of simultaneous GAP and GEF activities not yet resolved
   • Relative contributions of Gα12 vs. Gα13 to physiological signaling unclear
2. 2000 High

   Demonstration that Gα13 drives plasma membrane translocation of p115 RhoGEF in a palmitoylation-dependent manner established membrane recruitment as a key activation mechanism, separable from the physical Gα13–p115 interaction.

   Evidence Co-immunoprecipitation and fluorescence microscopy with palmitoylation-deficient Gα13 mutants in transfected cells

   PMID:10747909

   Open questions at the time

   • Identity of the membrane-targeting determinant on p115 RhoGEF itself unknown
   • Whether endogenous receptors use the same translocation mechanism not shown
3. 2001 High

   Mapping of intramolecular regulatory elements showed that the PH domain supports catalytic activity while the C-terminal region autoinhibits it, and that endogenous p115 RhoGEF translocates upon GPCR ligand stimulation, linking domain architecture to signal-dependent activation.

   Evidence Domain deletion mutants with in vitro GEF assays; subcellular fractionation of endogenous protein after LPA/S1P stimulation

   PMID:11384980

   Open questions at the time

   • Atomic mechanism of autoinhibition not resolved at this stage
   • Role of the C-terminal region as a protein–protein interaction platform only partially explored
4. 2007 High

   Identification of ARHGEF1 (together with LARG) as fibronectin-specific integrin-activated RhoGEFs placed the protein in the adhesion-to-cytoskeleton signaling axis beyond GPCR pathways.

   Evidence Affinity pulldown for active GEFs, siRNA knockdown, and dominant-negative mutant in cells on fibronectin

   PMID:17971419

   Open questions at the time

   • Direct integrin–ARHGEF1 binding not demonstrated
   • Upstream kinases linking integrin engagement to ARHGEF1 activation not identified
5. 2009 High

   Discovery that neighboring epithelial cells target p115 RhoGEF to the basolateral surface via microtubules during apoptotic extrusion revealed a non-GPCR, cytoskeleton-directed mechanism of spatial activation with direct morphogenetic consequence.

   Evidence Live-cell imaging with microtubule perturbation and myosin inhibition in epithelial monolayers

   PMID:19720875

   Open questions at the time

   • Molecular link between microtubule plus-ends and p115 RhoGEF targeting unknown
   • Whether this mechanism operates in vivo tumor cell extrusion untested
6. 2010 High

   Identification of JAK2-mediated Tyr738 phosphorylation as the angiotensin II–induced activation switch, coupled with the hypertension-resistant phenotype of smooth-muscle-specific Arhgef1 knockout mice, established ARHGEF1 as a central mediator of vascular tone.

   Evidence Phospho-site mutagenesis, kinase inhibition, conditional knockout mice, and blood pressure measurement

   PMID:20098430

   Open questions at the time

   • Whether other tyrosine sites contribute to activation in vascular smooth muscle not resolved
   • Downstream effectors beyond ROCK not fully mapped in vivo
7. 2011 High

   Crystal structures of the DH/PH cassette with and without the linker region revealed that the linker disorders the N-terminal DH extension required for catalysis, defining the structural basis of autoinhibition (the 'GEF switch').

   Evidence X-ray crystallography and SAXS combined with in vitro GEF activity assays of truncation constructs

   PMID:21064165

   Open questions at the time

   • How Gα13 binding relieves this autoinhibition structurally not captured in a single complex structure
8. 2012 High

   Mapping the Gα13–DH domain interface to the α3b helix showed that Gα13 contacts a surface distinct from the RhoA-binding face, with the RH domain facilitating this interaction, explaining how Gα13 allosterically stimulates exchange activity.

   Evidence SAXS, site-directed mutagenesis of DH and Gα13 helical domains, and in vitro GEF assays

   PMID:22661716

   Open questions at the time

   • Full atomic-resolution structure of the ternary Gα13–p115–RhoA complex lacking
   • Whether linker displacement and DH-domain contact are sequential or concerted not determined
9. 2016 Medium

   Parallel studies in T lymphocytes and mechanotransduction showed ARHGEF1 is tyrosine-phosphorylated downstream of JAK/Src-family kinases upon chemokine or mechanical stimulation to activate both RhoA and Rac1, broadening its effector spectrum beyond RhoA alone and linking it to integrin inside-out signaling and YAP/TAZ mechanosensing.

   Evidence siRNA knockdown, LFA-1 affinity/adhesion assays, phosphorylation analysis, RhoA/Rac1 pulldowns, YAP/TAZ localization

   PMID:26985018 PMID:27489999 PMID:27573018 PMID:27986909

   Open questions at the time

   • Direct phosphorylation by Src-family kinases at specific residues not mapped
   • Whether Rac1 activation is direct or via an intermediate pathway unresolved
   • Relative contribution of ARHGEF1 vs. GEF-H1 in mechanotransduction not quantified
10. 2017 High

    In vivo studies using Arhgef1-knockout mice with bone marrow reconstitution demonstrated that leukocyte-intrinsic Arhgef1 is required for angiotensin II–induced integrin activation, endothelial adhesion, and atherosclerosis development, establishing a cell-autonomous immune function.

    Evidence Bone marrow chimera in LDLR−/− mice, leukocyte adhesion assay, integrin activation assay

    PMID:29130930

    Open questions at the time

    • Specific Gα subunit upstream of Arhgef1 in leukocytes not identified
    • Whether the vascular and immune roles synergize in atherogenesis not dissected
11. 2019 High

    Human loss-of-function mutations in ARHGEF1 were shown to cause defective RhoA-dependent actin polymerization and ROCK-mediated AKT restraint in lymphocytes, rescued by ARHGEF1 re-expression, establishing ARHGEF1 deficiency as a cause of primary immunodeficiency.

    Evidence Whole-exome sequencing, RhoA/actin/AKT assays in patient lymphocytes, rescue by ARHGEF1 expression or pharmacological RhoA activation

    PMID:30521495

    Open questions at the time

    • Full clinical spectrum of ARHGEF1 deficiency in additional kindreds not defined
    • Whether the AKT dysregulation drives lymphomagenesis not tested
12. 2022 Medium

    FRET-based kinetic analysis revealed that p115 RhoGEF has a much shorter interaction time with Gα13 than LARG or PDZ-RhoGEF, determined by a single rgRGS-domain residue, suggesting that differential kinetics tune signaling output among the three RH-RhoGEFs.

    Evidence Single-cell FRET kinetics, site-directed mutagenesis, and in vitro GAP assay

    PMID:36434027

    Open questions at the time

    • Physiological consequence of altered interaction kinetics not demonstrated in native tissue
    • Whether kinetic differences translate to distinct downstream signaling dynamics unknown

• A high-resolution structure of the full-length Gα13–p115 RhoGEF–RhoA ternary complex and the precise mechanism by which tyrosine phosphorylation at Tyr738 allosterically activates GEF activity remain unresolved.
• No ternary complex structure available
• Structural basis of phospho-Tyr738-mediated activation unknown
• In vivo redundancy among RH-RhoGEFs not systematically addressed